This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to The Market Chronicle to get the Daily Monster Market Commentary and join the 2,892 subscribers getting it for FREE!
Twitter and AMD Options Stand Out, Is There A Double Top In Biotech?
The stock market overall had another dull day, with the S&P 500 down less than 10 bps, closing at 2,747. Like I had mentioned yesterday, the S&P managed to hang around support at 2,746. Again, there is a chance we could try for 2,740, but my expectations continue to suggest higher equity price over the short-term.
10-year treasury yield continue to head lower, and I think they head toward the 2.6 percent region.
The NASDAQ Biotech ETF, $IBB, looks headed towards $111.50, where there is a steady level of support there. If that cracks, we have much lower to go, and it makes the downtrend more powerful.
The XBI looks scary now, and move to $93.50 nears. But the formation of what appears to be double top is what worries me. The only question, where is the neckline in this mess? It is probably not $93.50, and that is good news. It looks to be in a range of $88 or $89, and break below that would confirm the double-top, and a move much lower.
Subscribe to the The Market Chronicle to get it Daily and join the 2,892 subscribers getting it for FREE!
Regeneron continued its downward move today after getting close to resistance around $351.
Biogen continues to try to turn higher.
There was a lot of activity again in AMD options with 142,000 put contracts trading at $10 strike price for April 20 expiration. According to data from Trade Alert, 52 percent of the volume occurred on the bid, and that would tell me someone was likely buying the puts, but we won’t know until open interest updates tomorrow. There was already open interest of 267k contracts. Meanwhile, the $11 puts also traded about 43,000 contracts, but again the open interest going into today was about 265k.
The chart is near a major breakdown, and should it fall through $11.20, it is likely to head towards $10.70, but it could be as much as $9.75
Broadcom reported better than expected fiscal first-quarter revenue of $5.331 billion, ahead of estimates for 4.998 billion, while beating on EPS at $5.12 per share versus estimates of $5.06 according to thefly.com. The guidance for revenue of $5 billion for the fiscal second quarter is pretty much in line with expectations. To me, after the first look, there was nothing in this report that wasn’t as expected. I think the overall trend in Broadcom continues to stay favorable, with the stock continuing to rise.
Twitter is close to a big breakout and a rise above $36.75, as I noted in an Investopedia article, sends shares much higher, perhaps to $46. The holder of January 2019 $37 calls, pared their position back yesterday, with the open interest being reduced to 89,000 contracts. The calls trade at $6.25, and that makes the open contracts worth about $55 million. Whoa! To think it was about $66 million yesterday before they sold some of those calls.
I went over this in the premium video yesterday and showed the build-up in the open interest when I think the position was first purchased.
Again, it surprises me how slow this trader is in lowering the position given the massive gains. In the article I wrote yesterday, I noted the open interest jumped around the end of August, and the price of Twitter was much lower, like in the upper-teens, which means the options were likely bought for a very cheap premium.
It makes me think they see more gains for the stock price.
That is it!
Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets
Free Articles Written By Mike:
Join our 2,892 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Michael Kramer and the clients of Mott Capital own shares of ACAD, TSLA
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2018 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #sp500 #biotech #biogen #regeneron #twitter #amd #broadcom